Publications by authors named "N Y Gabrail"
Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in patients with advanced cancers as both a monotherapy and in combination with chemotherapy. In a phase II study of patients with advanced biliary tract cancer who had received one or two prior therapies, CTX-009 with paclitaxel demonstrated a 37.
View Article and Find Full Text PDFOral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Lancet Haematol
January 2024
Article Synopsis
- The study investigates the safety and pharmacokinetics of oral decitabine combined with cedazuridine versus intravenous decitabine in patients with myelodysplastic syndromes or chronic myelomonocytic leukaemia.
- It involved a phase 3 multicentre trial with participants randomly assigned to receive either oral or IV treatment in a crossover design, allowing for direct comparison of the two methods.
- The primary goal was to measure and compare total decitabine exposure over a 5-day period for both formulations to determine the effectiveness of the oral treatment option.
Anemia is a common side effect of myelosuppressive chemotherapy; however, chemotherapy-induced anemia (CIA) management options are suboptimal. We evaluated the efficacy and safety of roxadustat in this setting. This open-label Phase 2 study included patients with non-myeloid malignancies and CIA (hemoglobin [Hb] ≤10 g/dL) who had planned concurrent myelosuppressive chemotherapy for ≥8 additional weeks.
View Article and Find Full Text PDFBackground: Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and associated with improved antitumor activity. The objective of this trial was to determine the recommended phase 2 doses (RP2Ds) and to assess the safety and efficacy of the programmed cell death protein 1 (PD-1) inhibitor dostarlimab in combination with (1) the poly(ADP-ribose) polymerase inhibitor niraparib with or without vascular endothelial growth factor inhibitor bevacizumab or (2) carboplatin-paclitaxel chemotherapy with or without bevacizumab, in patients with advanced cancer.
Methods: IOLite is a multicenter, open-label, multi-arm clinical trial.